View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 18, 2021updated 11 Jul 2022 2:22pm

Allogeneic CAR-T trials paused due to chromosomal abnormality detected in patient

Allogene Therapeutics’ stocks fell by 46% after the CAR-T trials were put on hold, though they have now recovered to an extent.

By GlobalData Healthcare

Trials featuring Allogene Therapeutics’ allogeneic CAR-T products have been placed on hold by the US Food and Drug Administration (FDA) following a reported chromosomal abnormality in a patient who received ALLO-501A as part of the ALPHA2 study. Further characterisation of the abnormality will be undertaken, with Allogene giving updates to the FDA over the coming weeks.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The chromosomal abnormality was detected in a Stage IV transformed follicular lymphoma patient with a c-myc rearrangement. The patient had previously failed two lines of therapy and was unable to receive an autologous CAR-T product due to manufacturing issues that meant their cells failed to expand sufficiently. Following the receipt of ALLO-501A, a partial response was seen, and Allogene has reported that the CAR-T cells expanded, peaking on Day 28. A bone marrow biopsy was performed due to the development of pancytopaenia (low levels of red cells, white cells and platelets), which detected the chromosomal abnormality in the ALLO-501A CAR-T cells. The patient was, ultimately, able to proceed to an allogeneic stem cell transplant.

ALLO-501 and ALLO-501A are CD19-directed therapies currently being investigated in patients with relapsed or refractory non-Hodgkin’s lymphomas as part of the ALPHA and ALPHA2 trials. TALEN gene editing is used to disrupt the T-cell receptor α gene, and is predicted to reduce the incidence of graft-versus-host disease. The CD52 gene is also edited to allow for depletion of host T-cells using Allogene’s anti-CD52 antibody, ALLO-647. A pivotal Phase II trial is planned for next year.

This news is damaging to Allogene, however, which initially saw its stocks plummet 46% following the announcement, though these have now recovered somewhat. It is likely to be several months before a resolution is reached and the trials recommenced due to the required time to properly investigate the abnormality. Despite this, more than 100 patients have so far been treated with Allogene’s allogeneic CAR-T products across two trials, indicating such a phenomenon is likely relatively rare. If the CAR-T product is found to be the cause of the pancytopaenia but Allogene can demonstrate that this is the only consequence, that the abnormality is rare and that the pancytopaenia is easily managed, the hold could potentially be lifted.

The clinical results released so far from Allogene’s Phase I trials have been compelling, suggesting that any risk of developing chromosomal abnormalities may be outweighed by the potential benefits of therapy. Data presented at the American Society of Clinical Oncology meeting this year demonstrated an objective response rate of 75%, with a complete response seen in 47% of patients in the ALPHA trial. Importantly, the median time to treatment was just five days from enrollment to lymphodepletion.

The lack of treatments for patients with relapsed or refractory non-Hodgkin’s lymphomas is a major unmet need, and while autologous CAR-T has been transformative for this patient group, this approach is not without its pitfalls. It remains the case that for many patients, autologous CAR-T is impossible to access either due to geographical barriers, or because of clinical features of their disease that can mean a product cannot be generated quickly enough, or at all. Allogene is at the forefront of the race to develop an allogeneic product that could be given more easily to a wider selection of patients. The abnormality is certainly a concern, but pioneers in any field can expect to face unforeseen roadblocks, and it is hoped these can be ultimately overcome.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena